Horseshoe Crab Welfare and Biomedical Use

Horseshoe crabs are harvested for their blue blood used in vaccine safety testing, with millions bled annually and their sentience status increasingly questioned.

Key Facts

Approximately 500,000 horseshoe crabs are harvested annually in the US for limulus amebocyte lysate (LAL) production
LAL detects bacterial endotoxins and is used to test all injectable pharmaceuticals and medical devices
Up to 30% of bled crabs may die from the process; the remainder are returned to the ocean
Horseshoe crab populations have declined significantly in parts of their range
Recombinant Factor C (rFC) - a synthetic alternative to LAL - has been developed and validated as an equivalent
Horseshoe crabs are not classified as animals in some regulatory frameworks, limiting welfare protection

Welfare Considerations

The welfare status of horseshoe crabs is uncertain given their phylogenetic position as chelicerates rather than insects or crustaceans. They possess nociceptors and the 30% mortality rate from bleeding suggests the process causes significant physiological harm. The availability of rFC as a validated synthetic alternative means continued horseshoe crab bleeding is not a biological necessity but a regulatory inertia problem. Transitioning to rFC would eliminate welfare concern and remove harvest pressure from declining populations simultaneously.

What You Can Do

Support campaigns for regulatory approval and adoption of rFC as the standard alternative to LAL
Advocate for pharmaceutical and medical device regulators to accept rFC validation data
Back research institutions developing horseshoe crab-free alternatives to biomedical testing
Raise awareness that synthetic LAL alternatives exist and are validated for safety testing
Contact pharmaceutical manufacturers about their position on transitioning to rFC